Results from a recent large study indicate that current or recent protease inhibitor use does not increase the risk of stroke or sudden death in people with HIV. However, the researchers did find a small increased risk over time with longer exposure to protease inhibitors.

Based on their results, the study authors recommended future studies to look for links between individual protease inhibitors and increased risk of death. However, they also noted that deaths are rare, which makes it difficult…

Results from a recent Swiss study indicate that the higher risk of developing lung cancer in people with HIV compared to the general population arises from heavy smoking, not HIV infection.

Based on the results, the study authors recommended implementing strategies to reduce smoking, and therefore lung cancer risk, in HIV-positive adults.

The study authors also speculated that links between lung cancer and HIV or immune deficiency in previous studies were caused by overrepresentation of people with advanced HIV infections…

Results from a recent British study indicate that low levels of residual HIV – below the level that is a goal for antiretroviral therapy – can still lead to treatment failure.

Based on their results, the study authors suggested that even lower cutoff levels for residual HIV in the blood may be necessary to avoid treatment failure.

The goal of antiretroviral therapy is to reduce viral loads (amount of HIV in the blood) to levels that are undetectable with most…

Results from a recent French study indicate that diseases such as diabetes, high blood pressure, and depression, but not HIV, increase the risk that people with HIV will stop work prematurely.

The researchers also found that more than a third of study participants had stopped working five years after the start of the study.

Based on the results, the study authors concluded that people with HIV are still at a substantial risk of stopping employment after their diagnosis and recommended…

Results from a recent Japanese study indicate that a Viread-based antiretroviral therapy regimen causes greater loss of kidney function than a Ziagen-containing therapy, particularly in people with HIV who weigh less than about 130 pounds.

Based on the results, the study authors recommended that people with HIV who are taking Viread, Truvada, or Atripla (which both contain Viread) and have a low body weight be monitored for loss of kidney function at least twice per year, particularly during their first…